MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Function, a medical and health company on a mission to empower humanity to reach 100 years, has launched the Function Connector, an integration with Claude, the large language model developed by Anthropic. The integration allows members to authorize Claude to access lab results and to provide guided health advice that is based on these results. Function said the goal is to make members understand their health-related matters in a simple way that can guide smarter, healthier choices.
The Function Connector provides tools that make accessing health data simple. These include the option of an overview of lab results, biomarker category summaries and the health protocol tool aimed at nutrition. It uses secure authentication and encryption, ensuring that your data is only at a summary level, protecting personal information from being used as training data. The connector for Claude is available to members of Function.
Posted by MedCloudInsider Editors on 01/12/20260 comments
Recent research reveals that Biotronik Neuro's remote monitoring with real-time visibility into spinal cord stimulation (SCS) usage can support a more effective, long-term approach to managing implanted neurostimulation devices. Biotronik is a leading medical device company aimed at developing improvements for heart and blood vessel diseases. The research examined how continuous data on stimulation patterns and patient engagement can help clinicians better understand therapy adherence, optimize programming and identify issues earlier than traditional follow-up methods. Researchers claim that the approach addresses a long-standing gap in post-implant care, where limited visibility has made it difficult to assess how devices are actually used outside the clinic.
Spinal cord stimulation is widely used for chronic pain, but outcomes vary significantly over time. The study’s findings suggest that real-time utilization data could become a foundation for more proactive device management, aligning neuromodulation with broader trends toward connected medical devices and continuous care models in chronic disease treatment. Other key findings show that 96.8 percent of patients were actively using therapy with less than 1 percent of patients classified as virtual explants.
Posted by MedCloudInsider Editors on 01/05/20260 comments
Mira Precision Health, specialists in precision medicine diagnostics, has announced the U.S. launch of ToxNav Advantage, an AI-based clinical decision support platform, at the 2026 ASCO Gastrointestinal Cancers Symposium. The software is designed to help oncologists assess and manage treatment-related toxicity risk by analyzing patient-specific data alongside therapy characteristics. Mira intends for ToxNav Advantage to support more informed treatment planning, particularly for gastrointestinal cancers where adverse effects can limit dose intensity or lead to early discontinuation.
The launch comes as oncology teams face growing complexity in balancing efficacy and tolerability across expanding treatment options. Key features include comprehensive analysis of gene variants, rapid turnaround time for actionable results and clear optimized reports that are clinician-friendly with actionable insights that prevent life-threatening toxicities. By emphasizing prospective toxicity insights, Mira’s approach reflects broader interest in using AI to support individualized care planning. For health systems, tools that reduce avoidable adverse events may also help improve quality metrics and resource utilization.
Posted by MedCloudInsider Editors on 01/05/20260 comments
The Veterans Health Venture Studio (VHVS), an engine designed to develop the pipeline of innovation, expands its Make-a-thon program, an innovation initiative that pairs VA clinicians, engineers, designers and veterans to rapidly develop solutions to unmet needs in health care delivery and daily living. The Make-a-thon is supported by the VA's Office of Healthcare, The American Legion and Microsoft. At its core, the program is powered by Microsoft with expert innovative training, experts and mentorship. The program focuses on hands-on collaboration, enabling teams to prototype assistive devices, clinical tools, and workflow improvements in short, intensive sprints. VA officials want the approach to help translate frontline insights into practical solutions more quickly than traditional procurement or research pathways.
The Make-a-thon model reflects a broader trend across healthcare systems toward co-design and clinician-led innovation. The VA’s national scale and direct access to veteran populations give it a distinct role. The aim of the program is designed to strengthen healthcare innovation and advance functional prototype projects with VA systems. For veterans, the initiative emphasizes functional outcomes—mobility, independence, and quality of life—while offering the VA a repeatable framework for advancing innovation aligned with real operational needs.
Posted by MedCloudInsider Editors on 01/05/20260 comments
Link Cell Therapies, a biotechnology oncology cell therapy company, has officially launched with the mission of accelerating the development of next-generation CAR-T therapies targeting both liquid and solid tumours. The company plans to apply innovations in cell engineering, tumor microenvironment modulation, and safety switches to overcome longstanding challenges that have limited CAR-T efficacy in solid malignancies. Link says its initial programs will advance through preclinical validation with IND-enabling goals, targeting tumor antigens with broad expression profiles and engineered features designed to improve persistence and reduce off-target toxicity.
Link’s strategy of combining advanced engineering and adaptive safety mechanisms aligns with competitors' efforts to target solid tumor niches. For developers and clinicians, the company’s entry underscores the evolving landscape of cellular therapies where addressing solid malignancies remains a key frontier. The LNK001 program is aimed at treating renal cell carcinoma with two unique antigens for RCC tumors. The unique technology could enable the development of multiple treatments for patients.
Posted by MedCloudInsider Editors on 12/15/20250 comments
BioTec, a specialized bio company, has introduced two new sulfur-based products designed for industrial and agricultural markets, expanding its portfolio with materials intended to improve performance in applications such as advanced coatings and soil treatment. The company highlighted its new offerings at recent domestic and international exhibitions, emphasizing its formulation technology and its potential to meet evolving customer specifications. BioTec says the products leverage its sulfur-derivative expertise and production infrastructure to deliver consistent quality and scalable supply.
The launches come as demand grows for specialty chemical solutions that balance performance with regulatory and sustainability requirements. BioTec’s focus on exhibition showcases signals its intention to broaden market awareness and customer engagement as it seeks to convert interest into commercial uptake across its target sectors.
Posted by MedCloudInsider Editors on 12/15/20250 comments
Astrin Biosciences, a cancer intelligence company, has established a scientific advisory board to support the development of its AI-enabled proteomics platform for early cancer detection. The new board includes clinicians and researchers with backgrounds in oncology, biomarker discovery and machine learning, who will advise on study design, validation strategies and clinical translation. The development of the board comes post the launch of Astrin's Certitude Breast, a non-imaging screening test that can detect breast cancer in early stages. Astrin claims expert input is critical as it advances toward larger trials and potential regulatory pathways.
Interest in proteomic diagnostics has accelerated as researchers look beyond genomics for earlier and more accurate detection tools. For health systems seeking noninvasive screening options, platforms that leverage AI to interpret complex protein data could offer a complementary route to earlier detection and improved outcomes.
Posted by MedCloudInsider Editors on 12/08/20250 comments
Inductive Bio, an AI drug discovery partner, has received an award of up to $21 million to advance AI-driven toxicity models intended to improve drug safety assessment and reduce downstream development risk. The company will work with leading academic and biopharmaceutical partners to generate datasets, validate predictive models and evaluate how AI can better characterize off-target effects early in the R&D cycle. Inductive Bio aims to use the initiative to address persistent gaps in preclinical toxicity screening, where conventional models often fail to capture complex biological interactions that later lead to trial delays or program termination.
Safety-related attrition remains one of the most costly challenges in drug development. Inductive Bio’s effort, backed by a multi-institution consortium, reflects growing momentum toward shared datasets and collaborative validation frameworks. For biopharma R&D teams under pressure to cut costs and accelerate timelines, more accurate toxicity forecasting could materially reshape portfolio decision-making.
Posted by MedCloudInsider Editors on 12/08/20250 comments
ALR Technologies, a data management company, plans to relaunch its GluCurve Pet Continuous Glucose Monitor (CGM) in January 2026. The device is designed to help veterinarians and pet owners monitor glucose levels in diabetic cats and dogs through continuous, automated readings rather than periodic manual tests. Blood sugar readings are uploaded to the ALRT Veterinary Web Portal so that vets can easily monitor readings and adjust insulin levels accordingly for their patients.
The pet diabetes market has grown steadily as diagnosis rates rise and owners seek better tools to manage chronic conditions. A successful GluCurve relaunch could give clinics a more standardized tool for treatment adjustments, potentially reducing hypoglycemia risk and improving long-term outcomes for diabetic pets.
Posted by MedCloudInsider Editors on 12/08/20250 comments
CaliberMRI, an automation software and imaging phantoms company, has introduced the qDisc, a new quantitative MRI phantom designed to augment the functionality of the Medium ACR Phantom commonly used in clinical quality-assurance workflows. The qDisc provides stable reference materials for diffusion, T1/T2 relaxation and temperature measurements, allowing imaging teams to perform more comprehensive scanner performance checks without adding complex new equipment. The company says the device provides a practical option to gather metrics during routine scans. The harmonization of MRI scanners and AI software for analysis can be done using the qDisc, which complements CaliberMRI's existing offerings.
Interest in quantitative MRI is rising as hospitals and research centers adopt standardized metrics to compare imaging across scanners and sites. The qDisc’s integration with the ACR phantom offers a practical path for sites that want to expand quantitative QA without overhauling existing processes.
Posted by MedCloudInsider Editors on 12/01/20250 comments
Hoppr and Ferrum Health, an AI-insights service provider, have announced a partnership to launch a full foundation-model development suite designed specifically for healthcare organizations. The platform will allow hospitals, research centers and developers to build or fine-tune large medical AI models using their own imaging and clinical datasets while keeping all data within a secure, compliance-focused environment. The integrated suite offers development tooling, data curation, model training, evaluation frameworks, interoperability and seamless deployment into Ferrum's governance layer.
The initiative reflects growing interest in health-system–owned AI, where organizations want more control over model performance, data privacy and clinical integration. The Hoppr–Ferrum approach emphasizes end-to-end tooling tied directly to clinical governance. For health systems dealing with variable imaging protocols and diverse patient populations, localized model adaptation is increasingly viewed as essential for safe and reliable AI deployment.
Posted by MedCloudInsider Editors on 12/01/20250 comments
ScreenPoint Medical, an AI-powered technological company specializing in breast imaging to help detect breast cancer, showcased new advancements to its Transpara Breast AI Suite at RSNA 2025. The updated suite provides risk scoring, lesion detection and triage tools designed to help radiologists prioritize cases and identify cancers earlier, particularly in dense breast tissue. The company noted that Transpara is already in clinical use in more than 30 countries and is designed to integrate with existing PACS and reading workflows without major process changes.
Interest in breast imaging AI continues to grow as radiology groups face rising exam volumes and persistent staffing shortages. ScreenPoint’s long-standing focus on reader support and case triage positions Transpara as a mature option for clinics seeking incremental adoption rather than full workflow redesign. Another development included Transpara Risk that produces an image-based 5 year risk model for breast cancer along with Transpara Detection which is still being researched for investigational use only.
Posted by MedCloudInsider Editors on 12/01/20250 comments